RecruitingPhase 2NCT07347249

A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Studying Congenital factor VII deficiency

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hemab ApS
Intervention: Sutacimig(drug)
Enrollment: 18 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2026 – 2026

Study locations (1)

Royal London Hospital, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07347249 on ClinicalTrials.gov

Other trials for Congenital factor VII deficiency

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience LLC

See all trials for Congenital factor VII deficiency →

← Back to all trials